Community-based Post-exposure Prophylaxis for COVID-19

Community-based Post-exposure Prophylaxis for COVID-19: Results and Implications of Ayurveda Practice Guidelines

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04920773

Enrollment

216

Registered

2021-06-10

Start date

2021-05-03

Completion date

2021-06-06

Last updated

2021-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Post Exposure Prophylaxis

Brief summary

Specifically identified Ayurvedic preparations is recommended by ministry of AYUSH as post-exposure prophylaxis to efficaciously prevent a negative person who has come into contact with COVID-19-positive. Traditionally, recommended Ayurvedic preparations have been used as antioxidants, antimicrobial and anti-inflammatory properties. Particularly, Guduchi Ghanvati has been recognised with its ability to control viral attachment, viral replication and induce immune response in pre clinical settings, and found to be one among the most important drugs in Ayurveda to fight against COVID-19. However, known gap in guideline implementation and its impact on preventing active infection in exposed cases is unclear. Study aimed to increase the use of recommended AYUSH guidelines by having registered AYUSH physicians provide these medications, when indicated, in community based participants after known exposure to the SARS-CoV-2 coronavirus.

Interventions

OTHERGuduchi Ghanvati

500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily

OTHERStandard guidelines

Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Men or women 18 to 60 years of age * Household contact residing with the index case in the 14 days prior to index diagnosis within a residence without maintaining social distance * Access to device and internet for telephonic appointments and follow up

Exclusion criteria

* Currently hospitalised * Symptomatic with fever, cough, or shortness of breath * Use of anti-malarial treatment or chemoprophylaxis * Moderately or Severely ill for any co-morbid condition requiring medical assistance. * Cognitive impairment

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with active COVID-19	14-days following exposure	PCR- proven COVID-19

Secondary

Measure	Time frame	Description
Time to symptoms onset	14-days	Days until start of symptoms of COVID-19
Disease Severity	14 days	Visual Analog Scale of rating overall symptom severity (0 = no symptoms; 10 = most severe)

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026